Drainage Of Pleural Effusions in the Intensive Care Unit (DOPE-ICU) - Feasibility Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ultrasonography-guided pleural drainage.
- Who it may be relevant to
- Registry conditions: Pleural Effusions, Respiratory Failure. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Drainage of Pleural Effusions in the Intensive Care Unit in Adults With Respiratory Failure: A Randomised Clinical Feasibility Trial of Performing Versus Withholding Pleural Drainage
Overview
This trial evaluates the feasibility of ultrasound-guided pleural drainage versus no drainage in adult ICU patients with pleural effusions (fluid buildup around the lungs) and respiratory failure. Half of the patients will undergo drainage, while the other half will not unless their condition worsens to a prespecified degree. Outcomes include feasibility measures, clinical parameters, mortality, serious adverse events, and life support use over 90 days.
Detailed description
Pleural effusions are common in intensive care unit (ICU) patients and are often treated with fluid drainage guided by ultrasonography. While this can improve oxygenantion levels, it is unclear whether it leads to better overall outcomes, and the procedure carries risks such as bleeding or lung collapse. There is limited evidence and no randomised trials supporting this procedure in ICU patients with respiratory failure. The DOPE-ICU feasibility trial will assess the feasibility of evaluating pleural drainage in such patients. Eligible ICU patients will be randomly assigned to either receive drainage or no drainage unless their condition worsens to a prespecified degree. Feasibility outcomes include the proportion of patients receiving drainage, protocol adherence, and proportion of patients with consent withdrawal for follow-up. Clinical outcomes include death rates, serious adverse events, and life support use, all within 90 days. Process outcomes include oxygenation, pH and arterial carbon dioxide tension at prespecified time points. The trial aims to determine whether a larger, more definitive trial is feasible.
Interventions
- Procedure Ultrasonography-guided pleural drainage
Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
Primary outcome measures
- Intervention group separation (feasibility) [Time frame: 90 days]
Secondary outcome measures (12)
- Protocol adhearence (feasibility) [Time frame: 90 days]
- Recruitment proportion (feasibility) [Time frame: Through trial completion, estimated at 1 year.]
- Loss to follow-up (feasibility) [Time frame: 90 days]
- All-cause mortality (clinical outcome) [Time frame: 90 days]
- Serious adverse events (clinical outcome) [Time frame: 90 days]
- Days alive without life support (clinical outcome) [Time frame: 90 days]
- Days alive and out of hospital (clinical outcome) [Time frame: 90 days]
- Pleural infections (process outcome) [Time frame: After 24 hours and within 90 days from randomisation]
- 24-hour oxygenation (process outcome) [Time frame: 24 hours]
- 72-hour oxygenation (process outcome) [Time frame: 72 hours]
- 24-hour pH (process outcome) [Time frame: 24 hours]
- 72-hour pH (process outcome) [Time frame: 72 hours]
Eligibility criteria
Inclusion criteria
- Acute admission to the ICU.
- Age ≥ 18 years.
- Pleural effusion ≥ 2 cm in either pleural cavity assessed by ultrasonography, computed tomography or magnetic resonance imaging (measured between the parietal and visceral pleura perpendicularly to the chest wall at the largest-separation point).
- Respiratory failure defined as one or more of the following: any oxygen supplementation in an open system, invasive or non-invasive mechanical ventilation (including non-intermittent mask CPAP), or most recent arterial blood gas analysis with arterial partial pressure of carbon dioxide (PaCO2) > 6.0 kPa and pH < 7.35.
Exclusion criteria
- Mediastinal drain or pleural drain in situ on either side.
- Suspected or confirmed haemothorax (e.g., due to recent thoracic trauma or intrathoracic surgery).
- Suspected or confirmed pneumothorax (e.g., by anamnesis, on radiographic or ultrasonographic assessment, or by clinical presentation, e.g., due to presence of subcutaneous emphysema).
- Suspected or confirmed pleural empyema (e.g., by anamnesis or clinical presentation, or on CT, MRI or ultrasonographic assessment).
- Pleural malignancy (suspected or confirmed pleural lymphoma, pleural metastases or direct pleural invasion, or malignant mesothelioma).
- Antithrombotic treatment or coagulation deficiency incompatible with conducting pleural drainage as by local recommendations, and contraindications to reversal of this (clinical assessment).
- Clinically assessed absolute indication for therapeutic pleural drainage and:
- invasive or non-invasive mechanical ventilation or mask CPAP with PaO2/FiO2 ratio ≤ 13.3 kPa in the most recent ABG analysis.
- high-flow humidified oxygen therapy with a flow ≥ 50 L/min and a PaO2/FiO2 ratio ≤ 13.3 kPa in the most recent ABG analysis.
- persistent respiratory acidosis with a pH < 7.25 and a PaCO2 > 6.0 kPa in the most recent ABG analysis in spite of non-invasive ventilation for > 1 hour.
- Withdrawal from active therapy or brain death deemed imminent.
- Expected ICU stay < 24 hours from randomisation.
- Pregnancy (in females < 60 years of age, non-pregnancy must be confirmed by a negative urine or plasma human chorionic gonadotropin, or presence a condition incompatible with pregnancy, e.g., previous hysterectomy, or conducted caesarean section during current hospitalisation).
- Under coercive measures (i.e., ongoing involuntary hospital admission or under correctional authorities' jurisdiction).
- Consent not obtainable as per Danish legislation.
- Previously randomised in the DOPE-ICU feasibility trial.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Denmark · 6 centers
- Department of Anaesthesia and Intensive Care, Aalborg University Hospital — Aalborg
- ICU department 4131, Copenhagen University Hospital, Rigshospitalet — Copenhagen
- Department of Anaesthesia and Intensive Care, Nordsjællands Hospital, University of Copenh — Hillerød
- Department of Anaesthesiology and Intensive Care Medicine, Sygehus Lillebælt, Kolding — Kolding
- Department of Anaesthesia and Intensive Care, Zealand University Hospital, Køge — Køge
- Department of Anaesthesia and Intensive Care, Zealand University Hospital, Roskilde — Roskilde
Publications
- Worm MS, Moller MH, Bruun NH, Brochner AC, Bestle MH, Rasmussen BS, Schjorring OL. Drainage of Pleural Effusion in the Intensive Care Unit (DOPE-ICU) Feasibility Trial-Protocol and Statistical Analysis Plan. Acta Anaesthesiol Scand. 2026 May;70(5):e70233. doi: 10.1111/aas.70233. PMID 41952333
Identifiers
NCT: NCT06709456 · N-20240027 · FID4401466 · 2024-0049